GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » PB Ratio

Protalix BioTherapeutics (FRA:PBDA) PB Ratio : 2.47 (As of May. 04, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Protalix BioTherapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-04), Protalix BioTherapeutics's share price is €1.043. Protalix BioTherapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was €0.42. Hence, Protalix BioTherapeutics's PB Ratio of today is 2.47.

The historical rank and industry rank for Protalix BioTherapeutics's PB Ratio or its related term are showing as below:

FRA:PBDA' s PB Ratio Range Over the Past 10 Years
Min: 2.5   Med: 8.77   Max: 266
Current: 2.52

During the past 13 years, Protalix BioTherapeutics's highest PB Ratio was 266.00. The lowest was 2.50. And the median was 8.77.

FRA:PBDA's PB Ratio is ranked worse than
51.07% of 1312 companies
in the Biotechnology industry
Industry Median: 2.48 vs FRA:PBDA: 2.52

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Protalix BioTherapeutics was 66.70% per year. The lowest was -80.80% per year. And the median was -17.10% per year.

Back to Basics: PB Ratio


Protalix BioTherapeutics PB Ratio Historical Data

The historical data trend for Protalix BioTherapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics PB Ratio Chart

Protalix BioTherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 3.84

Protalix BioTherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 127.17 3.56 3.11 3.84

Competitive Comparison of Protalix BioTherapeutics's PB Ratio

For the Biotechnology subindustry, Protalix BioTherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's PB Ratio falls into.



Protalix BioTherapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Protalix BioTherapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.043/0.422
=2.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Protalix BioTherapeutics  (FRA:PBDA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Protalix BioTherapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Protalix BioTherapeutics (FRA:PBDA) Business Description

Traded in Other Exchanges
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.

Protalix BioTherapeutics (FRA:PBDA) Headlines

No Headlines